Page 12 - Managing Science Editor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Managing science editor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Managing Science Editor Today - Breaking & Trending Today

In MS Patients, Mindfulness Helps to Reduce Depression, Fatigue

Depression and fatigue are common in people with MS. While fatigue results from MS-related chronic inflammation and neuronal damage, depression is caused by psychological and social factors that may not be directly related to multiple sclerosis.
Both depression and fatigue may be managed through mindfulness-based interventions, which are designed to boost mental well-being by purposefully staying present in the moment and acknowledging one’s feelings in an honest but nonjudgmental way. Trait mindfulness is defined as a permanent state of paying attention to the present moment in all aspects of life.
Hypothesizing that depression mediates the association between mindfulness and fatigue, a team of German researchers now explored the relationship between trait mindfulness, depression, and fatigue in MS patients. ....

Faisha Abdullah , University Of Lisbon , Weill Cornell Medical College , Biomedical Sciences , University Of Houston , Epidemiological Studies Depression Scale , Wuerzburger Fatigue Inventory , Multiple Sclerosis , Freiburg Mindfulness , Expanded Disability Status Scale , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஆயிஷா அப்துல்லா , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , வெயில் கார்னெல் மருத்துவ கல்லூரி , உயிர் மருத்துவ அறிவியல் , பல்கலைக்கழகம் ஆஃப் ஹூஸ்டன் , பல ஸ்க்லரோசிஸ் , விரிவாக்கப்பட்டது இயலாமை நிலை அளவு , மூலக்கூறு உயிரியல் , யுனிவர்சிடேட் நோவா டி லிஸ்போவா , நிர்வகித்தல் அறிவியல் ஆசிரியர் ,

#AANAM – Tysabri in MS Improves Quality of Life, Reduces Infection Risk

Click here to subscribe to the Multiple Sclerosis News Today Newsletter!
5
(2)
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treatment with Tysabri (natalizumab) can improve mental and social health in people with multiple sclerosis (MS), according to new data presented at the 2021 virtual American Academy of Neurology annual meeting (AANAM).
Data presented at AANAM also indicate that less frequent dosing of Tysabri can reduce the risk of rare brain infections, while still lowering MS disease activity.
Tysabri, by Biogen, is an approved treatment for relapsing forms of MS, and works by blocking inflammatory immune cells from getting into the brain. In clinical trials, Tysabri has been demonstrated to lower the rate of MS relapses and to ease symptoms. Treatment with Tysabri also h ....

United States , Maha Radhakrishnan , Carrie Hersh , Program Database , University Of Lisbon , Ms Partners Advancing Technology , Biomedical Sciences , Society Of America , University Of Pittsburgh , American Academy Of Neurology , Health Solutions , Multiple Sclerosis News Today , American Academy , Cleveland Clinic , Real World Cohort , Patients With Multiple Sclerosis , Advancing Technology , Neurological Disorders , Extended Interval Dosing , Reduced Risk , Progressive Multifocal Leukoencephalopathy , Updated Analysis , Molecular Pathology , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor ,

#AANAM – Abnormally Warm Weather Tied to More ER Visits

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care, new research shows.
The findings indicate that people with health conditions like MS may be at increased risk of health problems as temperatures rise due to climate change, according to Holly Elser, PhD, an epidemiologist and medical student at Stanford University.
The idea for this study, according to Elser, originated with a MS patient during a routine medical appointment: “[the patient] mentioned off-handedly, ‘you know, my MS gets really bad when it’s hot outside, ” said Elser. ....

United States , France General , Holly Elser , University Of Lisbon , University Of Pittsburgh , Society Of America , American Academy Of Neurology , Stanford University , Biomedical Sciences , Multiple Sclerosis News Todayteam , American Academy , Paris Agreement , Molecular Pathology , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஹோலி எல்சர் , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , சமூகம் ஆஃப் அமெரிக்கா , அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , உயிர் மருத்துவ அறிவியல் , அமெரிக்கன் கலைக்கழகம் ,

#AANAM – COVID-19 Often Leads to Flares in MS Patients, Survey Finds

#AANAM – COVID-19 Often Leads to Flares in MS Patients, Survey Finds
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Afagh Garjani , University Of Lisbon , University Of Pittsburgh , University Of Nottingham , Society Of America , American Academy Of Neurology , Biomedical Sciences , Multiple Sclerosis News Todayteam , Multiple Sclerosis , Last March , Expanded Disability Status Scale , Hospital Anxiety , Depression Scale , Molecular Pathology , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , பல்கலைக்கழகம் ஆஃப் நாட்டிங்ஹாம் , சமூகம் ஆஃப் அமெரிக்கா , அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் ,

#AANAM – Ublituximab Reduced MS Relapse Rate, Disability Progression

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’ annualized relapse rates and lowering the number of brain lesions over nearly two years, according to data from the ULTIMATE clinical trials.
“The results of the ULTIMATE I and II studies show that not only did ublituximab effectively reduce relapses in patients with RMS, but had a profound effect on suppressing inflammatory activity,” Steinman, the global study chair for the two trials, said in a press release. ....

Long Beach , United States , Stanford University , Lawrence Steinman , University Of Lisbon , American Academy Of Neurology , Biomedical Sciences , Columbia University , Multiple Sclerosis News Todayteam , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , நீண்டது கடற்கரை , ஒன்றுபட்டது மாநிலங்களில் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , லாரன்ஸ் ஸ்டெய்ன்மேன் , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் , உயிர் மருத்துவ அறிவியல் , கொலம்பியா பல்கலைக்கழகம் , மூலக்கூறு உயிரியல் , யுனிவர்சிடேட் நோவா டி லிஸ்போவா , நிர்வகித்தல் அறிவியல் ஆசிரியர் ,